A rigorous cost-benefit assessment can help to chart a cost-effective path forward.
James P. Catania
Advertisement
James P. Catania is a managing consultant at Tunnell Consulting
Articles by James P. Catania
Executive management leadership is essential in the effective implementation of QbD.
By identifying and eliminating non-value-added activities, drug manufacturers can avoid falling into the same cost-traps in the future.
Advertisement
Latest Updated Articles
Quality by Design: The Case for Change (Part II)May 1st 2011
Quality by Design: The Case for ChangeMarch 1st 2011
How to Reduce Unnecessary Compliance CostsJuly 1st 2010
Advertisement
Advertisement
Trending on BioPharm International
1
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
2
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
5